Search Results

Robocath announces that it has raised €5 million to support the rollout of its robotic platform in strategic European target markets.

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center (MTC) in Rouen will use its R-One™ robot for future training. Founded in 2017, the MTC is a new center dedicated to training healthcare professionals in a number specialties, with special focus on new technologies.

Robocath announces during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

This latest financial contribution supplements the $5.6M raised by Robocath in a previous round of fundraising in May.

Robocath announces today the creation of its medical advisory board, including global experts and recognized leaders in interventional cardiology.

The procedures were performed at Rouen University Hospital and Clinique Pasteur in Toulouse (France) and precede the first clinical study of its kind to be conducted in Europe

The board plays a key role in defining the clinical strategy of the company.

Percutaneous Coronary Intervention is a non-surgical procedure for the implantation of stent using a catheter to treat obstructive coronary artery disease and open up blocked or narrowed blood vessels.

On the morning of September 12, 2021, a complex endovascular intervention was performed at Changhai Hospital of China Naval Medical University by Professor Qing-Sheng Lu’s team using ALLVAS™, China’s first endovascular intervention robot developed by Shanghai Aopeng Medical Technology Co.